Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Income from Continuing Operations (2021 - 2025)

Senti Biosciences has reported Income from Continuing Operations over the past 5 years, most recently at 18539000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 18539000.0 for Q4 2025, down 16.33% from a year ago — trailing twelve months through Dec 2025 was 67852000.0 (down 12.91% YoY), and the annual figure for FY2025 was 67852000.0, down 12.92%.
  • Income from Continuing Operations for Q4 2025 was 18539000.0 at Senti Biosciences, down from 16782000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for SNTI hit a ceiling of 1178.0 in Q1 2021 and a floor of 43293000.0 in Q3 2023.
  • Median Income from Continuing Operations over the past 5 years was 15365500.0 (2022), compared with a mean of 15272313.3.
  • Biggest five-year swings in Income from Continuing Operations: crashed 997692.87% in 2022 and later skyrocketed 65.2% in 2024.
  • Senti Biosciences' Income from Continuing Operations stood at 3857088.0 in 2021, then plummeted by 306.16% to 15666000.0 in 2022, then fell by 16.63% to 18272000.0 in 2023, then increased by 12.78% to 15937000.0 in 2024, then dropped by 16.33% to 18539000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 18539000.0 (Q4 2025), 16782000.0 (Q3 2025), and 16528000.0 (Q2 2025) per Business Quant data.